Stocks in Action USA: Insmed, Alcoa, United Therapeutics
Reading Time: 4 minutes
Insmed (INSM) – Biotech Stock Poised for Rebound: Analysts Fuel Momentum with 45% Price Potential! The stock of Insmed is currently gaining significant momentum after Morgan Stanley upgraded the stock to "Overweight" and raised the price target from $166 to $212 – an upside potential of about 45%. HC Wainwright has also recently confirmed its Buy rating and increased the price target from $230 to $245. The bullish sentiment is driven by several operational catalysts: The medication BRINSUPRI is expected to generate $209 million in revenue...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
